Maintaining commercial compliance is not just a regulatory obligation but a fundamental cornerstone for sustainable growth in the intricate landscape of the life sciences industry.
Transparency reporting, ethical engagement with healthcare professionals (HCPs), and vigilant compliance monitoring are pivotal elements in this realm.
As we navigate the dynamic terrain of compliance risks, it becomes imperative to explore effective strategies and cutting-edge solutions that mitigate potential pitfalls and foster a culture of ethical conduct.
Today, we’re exploring the top 5 compliance risks in the life science industry that can result in regulatory fines, sanctions, product recalls, and other dire consequences. Let’s get started.
What Are Compliance Risks?
Compliance risks in life sciences are essentially landmines in your commercial activities. They arise from inconsistencies or oversights in adhering to complex regulations governing interactions with healthcare professionals (HCPs), marketing practices, data handling, and more.
Think of them as the wolves in sheep’s clothing of business; seemingly innocuous actions can trigger board and regulatory scrutiny if compliance protocols are ignored.
Imagine offering an HCP a lavish dinner to discuss your latest drug – a seemingly harmless gesture but potentially a kickback, landing you in hot water. Or picture promoting your product’s benefits for unapproved uses – a classic off-label promotion case.
Reasons To Avoid Compliance Risks
- Financial Hit: Non-compliance with regulations and guidelines in the life sciences industry can lead to a significant financial hit for companies, such as fines, penalties, and legal fees. These costs can be substantial and may impact the profitability of the company. Additionally, non-compliance can result in lost revenue due to product recalls, damage to the company’s reputation, and reduced sales due to the loss of customer trust.
- Reputational Damage: Compliance failures in the life sciences industry can significantly impact a company’s reputation. Negative media attention and public perception can damage a company’s brand image and result in a loss of customer trust. This can also lead to reduced sales and revenue, making attracting and retaining talented employees difficult.
- Legal Issues: Legal repercussions include civil and criminal penalties, lawsuits, and regulatory enforcement actions that can also bring your operations to a standstill.
How To Manage Compliance Risks?
Managing compliance risks requires a holistic approach that combines robust internal controls, leveraging data analytics, ongoing training, and a commitment to ethical business practices. Life sciences companies must stay well informed of regulatory changes, conduct regular risk assessments, and implement an efficient and effective compliance program to ensure adherence to guidelines.
Best Practices for Assessing And Managing Compliance Risk
The life sciences industry faces a complex and ever-evolving landscape of commercial compliance risks. Navigating these risks effectively requires a comprehensive and proactive approach. Here are some best practices for commercial compliance risk management in the life sciences industry:
Risk Assessment
- Conducting regular risk assessments is considered a best practice in life sciences commercial compliance. It helps companies identify potential risk areas and focus their compliance efforts on areas of highest risk.
Cross-functional Collaboration
- There must be good coordination between departments, including legal, compliance, medical affairs, and sales and marketing. This helps ensure compliance considerations are integrated into business decisions and compliance risks are identified and addressed early on.
Monitoring and Auditing
- Regular monitoring and auditing of business practices and transactions.
- Identify potential compliance issues early on.
- Ensure that corrective actions are taken in a timely manner.
Training and Education
- Providing regular training and education on compliance.
- This helps ensure that employees understand the requirements and the consequences of non-compliance, and it helps foster a culture of compliance within the organization.
Oversight
- The designated compliance officer and compliance committee oversee the compliance program. They ensure key risks have been identified and managed, providing support and guidance.
Leveraging Technology and Data
- Invest in compliance technology: Utilize compliance software and data analytics tools to automate tasks, monitor activities, and identify potential risks in real time.
- Data-driven decision-making: Use data and analytics to improve risk assessments, control measures, and resource allocation.
- Implement predictive analytics tools to identify and address potential compliance issues before they occur.
Continuous Improvement
- Continuous improvement of compliance programs over time.
- This includes regular review and updating of policies and procedures, ongoing employee training and education, and regular assessment of program effectiveness.
- Monitoring and Auditing basis of improvement.
Additional Considerations
- Third-Party Due Diligence: If the organization engages with third parties, conduct thorough due diligence to assess their compliance practices. Clearly define expectations in contracts and agreements and monitor third-party activities regularly.
- Global compliance: If your company operates in multiple countries, ensure you are aware of and comply with all relevant regional and international regulations.
- Regulatory engagement: Build positive relationships with regulatory agencies and actively participate in industry discussions to stay up-to-date on the latest regulatory developments.
How To Conduct a Compliance Risk Assessment?
- Establish a Risk Assessment Team: Assemble a cross-functional team with expertise in compliance, operations, and relevant business areas to ensure a comprehensive assessment.
- Define the Scope: Clearly define the scope of the risk assessment, specifying the business processes, regulatory requirements, and data sources to be evaluated.
- Identify Compliance Risks: Employ various risk identification techniques, such as brainstorming, document reviews, and interviews, to pinpoint potential compliance risks, such as regulatory violations, reputational damage, and financial penalties.
- Evaluate Risk Severity: Assess the potential impact and likelihood of each identified risk, categorizing them as low, medium, or high severity.
- Prioritize Risk Remediations: Develop a risk remediation plan, prioritizing the most severe risks and allocating resources accordingly.
- Monitor and Review: Continuously monitor and review the risk assessment process, updating.
Top 5 Compliance Risks Within the Life Sciences Industry
1. Kickbacks and Improper Financial Relationships
Kickbacks are payments or other incentives offered to HCPs/HCOs in exchange for using or prescribing a particular drug or medical device. This can lead to over or inappropriate prescribing and the use of unsafe or ineffective products, resulting in regulatory enforcement actions.
The U.S. Department of Justice has already advised that the relationship between healthcare professionals and patients be based purely on the betterment of patient outcomes.
Therefore, placing this specific risk in the first position on this list is essential as it showcases the imperativeness of mitigating these risks early on before the regulatory authorities do.
Case: In 2019, Insys Therapeutics agreed to pay $225 million to settle allegations that it had engaged in illegal kickback schemes to promote the use of its fentanyl-based drug.
2. Off-label Promotions
Promoting drugs or medical devices for uses not approved by regulatory authorities can result in serious legal consequences, including fines and reputational damage.
For this, there needs to be a peer review committee present within a life sciences company that reviews all the marketing material produced to promote a specific drug or medical device.
Case: 2012 GlaxoSmithKline agreed to pay $3 billion to settle allegations that it had engaged in off-label promotion of several drugs.
3. False Claims to Government Programs
Submitting inaccurate or misleading claims to government programs, such as Medicare and Medicaid Services (CMS), can lead to severe financial penalties and damage the company’s standing.
In 2020, the Department of Justice announced that a pharmaceutical agreed to pay $600 million to settle allegations regarding engaging in a fraudulent marketing scheme to promote the use of its opioid addiction treatment.
4. Data Integrity Issues
This can result in inaccurate or misleading Open Payments data being reported to the CMS, leading to increased regulatory and board scrutiny. The regulatory fines and penalties can range up to $1,150,000 and, combined with reputational damage, heightened scrutiny, and other aspects, compromise the growth of a life sciences company.
5. Grant Misconduct
Grant misconduct poses a significant risk to the integrity of educational activities within the life sciences industry. When educational grants are misused or diverted for purposes other than their intended unbiased educational objectives, it not only undermines the credibility of educational programs but also raises serious compliance concerns.
Such misconduct may include directing funds towards activities that serve personal interests or influence prescribing behaviors, rather than advancing genuine educational initiatives. This can result in allegations of bribery or improper influence, drawing regulatory scrutiny and potentially tarnishing the reputation of the parties involved.
Conclusion
Compliance risks within the life sciences industry demand strategic planning and a commitment to ethical conduct. As we’ve explored the top five compliance risks, it’s evident overlooking them isn’t an option because it can have dire consequences, ranging from financial penalties to a company’s reputation.
To mitigate these risks effectively, life sciences companies must adopt a proactive approach that encompasses robust internal controls, ongoing training, and leveraging data-driven technologies and data analytics. By prioritizing compliance and embedding it into the fabric of their operations, life sciences companies can foster a culture of integrity and trust.